Merck KGaA Q3 EBITDA Pre Edges Up On Sales Growth; Lifts FY26 Outlook

Merck KGaA raised its full-year adjusted earnings forecast to €6.4B, up from €6.3B, citing strong life science and electronics divisions, and the pending acquisition of Bio-Techne. Shares rose 3.1% on the news. CEO Beckmann emphasized strategic acquisitions and workforce reductions. The company expects no US sales of Mavenclad from November, better than prior guidance.

Merck KGaA reported Q3 2026 sales of €5.63B, up 5.8%, with stable adjusted EPS at €2.32. Healthcare sales rose 2.9% to €2.27B, while adjusted EBITDA pre remained at €819M. Reported earnings fell 49.8% to €1.04.

Merck (MRK) raised its 2026 profit forecast to €6.4 billion, citing stronger Q3 results and favorable exchange effects. Revenue guidance increased to €21.5B–€21.9B. Q3 net profit fell 49.9% YoY. Shares rose 2.2%. Merck plans to acquire Bio-Techne (TECH) for $11.3B.

Merck KGaA (MRCG) stock rose 2.2% to €154.88 after Q3 2026 results showed net profit fell 50% to €450M, but net sales grew 5.8% to €5.63B. The company raised its 2026 adjusted EBITDA and revenue guidance, citing strong demand in semiconductor solutions and an upcoming acquisition. Moody’s affirmed its A3 rating, and the DAX index hit a record high, supporting the rally.

Merck KGaA (MKGAF) reported Q3 Non-GAAP EPS of €2.32 and revenue of €5.63B, up 5.8% Y/Y. Organic growth was 5.1%, with foreign exchange effects adding 1.5%. EBITDA pre was stable at €1.7B, with a margin of 18.5%. The company raised its FY2026 outlook.

Merck KGaA (MRCG) reported a 50% drop in Q3 net profit to 450 million euros, citing high prior-year comparisons. Sales rose 5.8% to 5.63 billion euros. The company raised its 2026 guidance, expecting sales of 21.5-21.9 billion euros and adjusted EBITDA of 6.2-6.4 billion euros, citing strong demand in semiconductor solutions and rare disease treatments.